A preliminary study of cytokines in suicidal and nonsuicidal adolescents with major depression

Journal of Child and Adolescent Psychopharmacology

Volumn 19, Issue 4, 2009, Pages 423-430

  Gabbay, Vilma ^a,b   Klein, Rachel G ^a   Guttman, Leah E ^a   Babb, James S ^a   Alonso, Carmen M ^a   Nishawala, Melissa ^a   Katz, Yisrael ^a   Gaite, Marta R ^a,c   Gonzalez, Charles J ^a,d  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; CITALOPRAM; FLUOXETINE; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; LAMOTRIGINE; LITHIUM; METHYLPHENIDATE; MIRTAZAPINE; QUETIAPINE; RISPERIDONE; SERTRALINE; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROL GROUP; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE DURATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE DYSREGULATION; IMMUNE SYSTEM; MAJOR DEPRESSION; MALE; RATING SCALE; SCHOOL CHILD; SUICIDE ATTEMPT; SYMPTOMATOLOGY; TH1 CELL; TH2 CELL;

ADOLESCENT; AGE FACTORS; CHILD; CYTOKINES; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; SUICIDE; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 69549114806     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2008.0140     Document Type: Article

References (52)

1. th edition. Washington (DC): American Psychiatric Association, 1994.
2. Bonaccorso S, Marino V, Biondi M, Grimaldi F, Ippoliti F, Maes M: Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Disord 72:237-241, 2002. (Pubitemid 35351283)
3. Brambilla F, Perna G, Bellodi L, Arancio C, Bertani A, Perini G, Carraro C, Gava F: Plasma interleukin-1 beta and tumor necrosis factor concentrations in obsessive-compulsive disorders. Biol Psychiatry 42:976-981, 1997. (Pubitemid 27496427)
4. Brebner K, Hayley S, Zacharko R, Merali Z, Anisman H: Synergistic effects of interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha: Central monoamine, corticosterone, and behavioral variations. Neuropsychopharmacology 22:566-580, 2000. (Pubitemid 30219401)
5. Capuron L, Ravaud A, Dantzer R: Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy. J Clin Oncol 18:2143-2151, 2000. (Pubitemid 30324368)
6. Capuron L, Ravaud A, Gualde N, Bosmans E, Dantzer R, Maes M, Neveu PJ: Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology 26:797-808, 2001. (Pubitemid 32918284)
7. Carlin JM, Borden EC, Sondel PM, Byrne GI: Interferon-induced indoleamine 2,3-dioxygenase activity in human mononuclear phagocytes. J Leukoc Biol 45:29-34, 1989.
8. Cohen P, Pine DS, Must A, Kasen S, Brook J: Prospective associations between somatic illness and mental illness from childhood to adulthood. Am J Epidemiol 147:232-239, 1998. (Pubitemid 28093133)
9. Currier AR, Ziegler MH, Riley MM, Babcock TA, Telbis VP, Carlin JM: Tumor necrosis factor-alpha and lipopolysaccharide enhance interferon-induced antichlamydial indoleamine dioxygenase activity independently. J Interferon Cytokine Res 20:369-376, 2000.
10. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW: From inflammation to sickness and depression: When the immune system subjugates the brain. Nat Rev Neurosci 9:46-56, 2008. (Pubitemid 350295688)
11. Daubener W, MacKenzie CR: IFN-gamma activated indoleamine 2,3-dioxygenase activity in human cells is an antiparasitic and an antibacterial effector mechanism. Adv Exp Med Biol 467:517-524, 1999. (Pubitemid 32202197)
12. Denicoff KD, Rubinow DR, Papa MZ, Simpson C, Seipp CA, Lotze MT, Chang AE, Rosenstein D, Rosenberg SA: The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 107:293-300, 1987. (Pubitemid 17136929)
13. Denys D, Fluitman S, Kavelaars A, Heijnen C, Westenberg H: Decreased TNF-alpha andNKactivity in obsessive-compulsive disorder. Psychoneuroendocrinology 29:945-952, 2004. (Pubitemid 38716121)
14. Fujigaki S, Saito K, Sekikawa K, Tone S, Takikawa O, Fujii H, Wada H, Noma A, Seishima M: Lipopolysaccharide induction of indoleamine 2,3-dioxygenase is mediated dominantly by an IFN-gamma-independent mechanism. Eur J Immunol 31:2313-2318, 2001. (Pubitemid 32785349)
15. Gabbay V, Klein RG, Alonso CM, Babb JS, Nishawala M, De Jesus G, Hirsch GS, Hottinger-Blanc PM, Gonzalez CJ: Immune system dysregulation in adolescent major depressive disorder. J Affect Disord 115:177-182, 2009.
16. Irwin MR, Miller AH: Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav Immun 21:374-383, 2007.
17. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N: Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): Initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36:980-988, 1997. (Pubitemid 27272932)
18. Kim YK, Na KS, Shin KH, Jung HY, Choi SH, Kim JB: Cytokine imbalance in the pathophysiology of major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 31:1044-1053, 2007. (Pubitemid 46810095)
19. Kim YK, Lee SW, Kim SH, Shim SH, Han SW, Choi SH, Lee BH: Differences in cytokines between non-suicidal patients and suicidal patients in major depression. Prog Neuropsychopharmacol Biol Psychiatry 32:356-361, 2008.
20. Leo R, Di Lorenzo G, Tesauro M, Razzini C, Forleo GB, Chiricolo G, Cola C, Zanasi M, Troisi A, Siracusano A, Lauro R, Romeo F: Association between enhanced soluble CD40 ligand and proinflammatory and prothrombotic states in major depressive disorder: Pilot observations on the effects of selective serotonin reuptake inhibitor therapy. J Clin Psychiatry 67:1760-1766, 2006. (Pubitemid 44955158)
21. Leslie DL, Kozma L, Martin A, Landeros A, Katsovich L, King RA, Leckman JF: Neuropsychiatric disorders associated with streptococcal infection: A case-control study among privately insured children. J Am Acad Child Adolesc Psychiatry 47:1166-1172, 2008.
22. Maes M, Bonaccorso S, Marino V, Puzella A, Pasquini M, Biondi M, Artini M, Almerighi C, Meltzer H: Treatment with interferon-alpha (IFN alpha) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFN alpha-induced depressive and anxiety symptoms and immune activation. Mol.Psychiatry 6:475-480, 2001. (Pubitemid 32566102)
23. Maes M, Meltzer HY, Scharpe S, Bosmans E, Suy E, De MI, Calabrese J, Cosyns P: Relationships between lower plasma L-tryptophan levels and immune-inflammatory variables in depression. Psychiatry Res 49:151-165, 1993. (Pubitemid 24033139)
24. Maes M, Scharpe S, Meltzer HY, Okayli G, Bosmans E, D'Hondt P, Vanden Bossche BV, Cosyns P: Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: Further evidence for an immune response. Psychiatry Res 54:143-160, 1994.
25. Maes M, Bosmans E, De Jongh R, Kenis G, Vandoolaeghe E, Neels H: Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 9:853-858, 1997. (Pubitemid 27494150)
26. Mann JJ, Arango V, Marzuk PM, Theccanat S, Reis DJ: Evidence for the 5-HT hypothesis of suicide. A review of post-mortem studies. Br J Psychiatry 155:7-14, 1989.
27. Mendlovic S, Mozes E, Eilat E, Doron A, Lereya J, Zakuth V, Spirer Z: Immune activation in non-treated suicidal major depression. Immunol Lett 67:105-108, 1999. (Pubitemid 29191527)
28. Meyers CA: Mood and cognitive disorders in cancer patients receiving cytokine therapy. Adv Exp Med Biol 461:75-81, 1999. (Pubitemid 32187420)
29. Monteleone P, Catapano F, Fabrazzo M, Tortorella A, Maj M: Decreased blood levels of tumor necrosis factor-alpha in patients with obsessive-compulsive disorder. Neuropsychobiology 37:182-185, 1998. (Pubitemid 28256877)
30. Myint AM, Leonard BE, Steinbusch HW, Kim YK: Th1, Th2, and Th3 cytokine alterations in major depression. J Affect Disord 88:167-173, 2005.
31. Nowak G, Ordway GA, Paul IA: Alterations in the N-methyl-D-aspartate (NMDA) receptor complex in the frontal cortex of suicide victims. Brain Res 675:157-164, 1995.
32. Pandey GN, Dwivedi Y, Rizavi HS, Ren X, Pandey SC, Pesold C, Roberts RC, Conley RR, Tamminga CA: Higher expression of serotonin 5-HT(2A) receptors in the postmortem brains of teenage suicide victims. Am J Psychiatry 159:419-429, 2002. (Pubitemid 34184737)
33. Pavon L, Sandoval-Lopez G, Eugenia Hernandez M, Loria F, Estrada I, Perez M, Moreno J, Avila U, Leff P, Anton B, Heinze G: Th2 cytokine response in Major Depressive Disorder patients before treatment. J Neuroimmunol 172:156-165, 2006. (Pubitemid 43277501)
34. Peterson BS, Leckman JF, Tucker D, Scahill L, Staib L, Zhang H, King R, Cohen DJ, Gore JC, Lombroso P: Preliminary findings of antistreptococcal antibody titers and basal ganglia volumes in tic, obsessive-compulsive, and attention deficit/hyperactivity disorders. Arch Gen Psychiatry 57:364-372, 2000. (Pubitemid 30202327)
35. Pfeffer CR, McBride PA, Anderson GM, Kakuma T, Fensterheim L, Khait V: Peripheral serotonin measures in prepubertal psychiatric inpatients and normal children: Associations with suicidal behavior and its risk factors. Biol Psychiatry 44:568-577, 1998. (Pubitemid 28496684)
36. Robinson CM, Hale PT, Carlin JM: The role of IFN-gamma and TNF-alpha-responsive regulatory elements in the synergistic induction of indoleamine dioxygenase. J Interferon Cytokine Res 25:20-30, 2005.
37. Rothwell NJ, Hopkins SJ: Cytokines and the nervous system II: Actions and mechanisms of action. Trends Neurosci 18:130-136, 1995.
38. Seidel A, Arolt, V, Hunstiger M, Rink L, Behnisch A, Kirchner H: Cytokine production and serum proteins in depression. Scand J Immunol 41, 534-538, 1995.
39. Shaffer D, Gould MS, Fisher P, Trautman P, Moreau D, Kleinman M, Flory M: Psychiatric diagnosis in child and adolescent suicide. Arch Gen Psychiatry 53:339-348, 1996. (Pubitemid 26115307)
40. Simon NM, McNamara K, Chow CW, Maser RS, Papakostas GI, Pollack MH, Nierenberg AA, Fava M, Wong KK: A detailed examination of cytokine abnormalities in Major Depressive Disorder. Eur Neuropsychopharmacol 18:230-233, 2008.
41. Song C, Lin A, Bonaccorso S, Heide C, Verkerk R, Kenis G, Bosmans E, Scharpe S, Whelan A, Cosyns P, De Jongh R, Maes M: The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression. J Affect Disord 49:211-219, 1998. (Pubitemid 28218842)
42. Steiner J, Bielau H, Brisch R, Danos P, Ullrich O, Mawrin C, Bernstein HG, Bogerts B: Immunological aspects in the neurobiology of suicide: Elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatr Res 42:151-157, 2008. (Pubitemid 350061255)
43. Stone TW, Darlington LG: Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discov 1:609-620, 2002. (Pubitemid 37361524)
44. Takikawa O, Habara-Ohkubo A, Yoshida R: Induction of indoleamine 2,3-dioxygenase in tumor cells transplanted into allogeneic mouse: Interferon-gamma is the inducer. Adv Exp Med Biol 294:437-444, 1991.
45. Taylor MW, Feng GS: Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J 5:2516-2522, 1991.
46. Tonelli LH, Stiller J, Rujescu D, Giegling I, Schneider B, Maurer K, Schnabel A, Moller HJ, Chen HH, Postolache TT: Elevated cytokine expression in the orbitofrontal cortex of victims of suicide. Acta Psychiatr Scand 117:198-206, 2008. (Pubitemid 351207982)
47. Tsao CW, Lin YS, Chen CC, Bai CH, Wu SR: Cytokines and serotonin transporter in patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 30:899-905, 2006. (Pubitemid 43795377)
48. Tuglu C, Kara SH, Caliyurt O, Vardar E, Abay E:. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology (Berl) 170:429-433, 2003. (Pubitemid 38010515)
49. Van Gool AR, Fekkes D, Kruit WH, Mulder PG, Ten Hagen TL, Bannink M, Maes M, Eggermont AM: Serum amino acids, biopterin and neopterin during long-term immunotherapy with interferon-alpha in high-risk melanoma patients. Psychiatry Res 119:125-132, 2003. (Pubitemid 36829424)
50. Vassalli P: The pathophysiology of tumor necrosis factors. Annu Rev Immunol 10:411-452, 1992.
51. Wirleitner B, Neurauter G, Schrocksnadel K, Frick B, Fuchs D: Interferon-gamma-induced conversion of tryptophan: Immunologic and neuropsychiatric aspects. Curr Med Chem 10:1581-1591, 2003. (Pubitemid 36896559)
52. Yamada K, Iida R, Miyamoto Y, Saito K, Sekikawa K, Seishima M, Nabeshima T: Neurobehavioral alterations in mice with a targeted deletion of the tumor necrosis factor-alpha gene: Implications for emotional behavior. JNeuroimmunol 111:131-138, 2000. (Pubitemid 30792069)